- Home
- LBRDP vs TGTX Comparison
LBRDP vs TGTX Comparison
Compare LBRDP & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LBRDP
- TGTX
- Stock Information
- Founded
- LBRDP N/A
- TGTX 1993
- Country
- LBRDP United States
- TGTX United States
- Employees
- LBRDP 1900
- TGTX N/A
- Industry
- LBRDP Cable & Other Pay Television Services
- TGTX Biotechnology: Pharmaceutical Preparations
- Sector
- LBRDP Telecommunications
- TGTX Health Care
- Exchange
- LBRDP Nasdaq
- TGTX Nasdaq
- Market Cap
- LBRDP N/A
- TGTX 4.2B
- IPO Year
- LBRDP N/A
- TGTX 1995
- Fundamental
- Price
- LBRDP $24.96
- TGTX $32.04
- Analyst Decision
- LBRDP
- TGTX Strong Buy
- Analyst Count
- LBRDP 0
- TGTX 5
- Target Price
- LBRDP N/A
- TGTX $45.00
- AVG Volume (30 Days)
- LBRDP N/A
- TGTX 2.1M
- Earning Date
- LBRDP N/A
- TGTX 11-03-2025
- Dividend Yield
- LBRDP N/A
- TGTX N/A
- EPS Growth
- LBRDP N/A
- TGTX N/A
- EPS
- LBRDP N/A
- TGTX 0.36
- Revenue
- LBRDP N/A
- TGTX $454,069,000.00
- Revenue This Year
- LBRDP N/A
- TGTX $82.58
- Revenue Next Year
- LBRDP N/A
- TGTX $44.99
- P/E Ratio
- LBRDP N/A
- TGTX $88.81
- Revenue Growth
- LBRDP N/A
- TGTX 30.96
- 52 Week Low
- LBRDP N/A
- TGTX $21.16
- 52 Week High
- LBRDP N/A
- TGTX $46.48
- Technical
- Relative Strength Index (RSI)
- LBRDP 53.03
- TGTX 56.50
- Support Level
- LBRDP $24.80
- TGTX $31.29
- Resistance Level
- LBRDP $24.99
- TGTX $32.56
- Average True Range (ATR)
- LBRDP 0.23
- TGTX 1.15
- MACD
- LBRDP 0.02
- TGTX 0.32
- Stochastic Oscillator
- LBRDP 94.59
- TGTX 73.48
About LBRDP Liberty Broadband Corporation Series A Cumulative Redeemable Preferred Stock
Liberty Broadband Corp serves in the telecommunications industry in the United States. It provides cable services to both residential andsommercial businesses through its fiber, hybrid fiber, and coaxial cable infrastructure. The services provided by the company are residential services which include video services, internet services, voice services, and mobile services, commercial services which include small, and medium business and enterprise solutions, advertising services, and other services. The reportable segments of the company are GCI Holdings, Charter. The firm derives the majority of its revenue from GCI Holdings.
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.